

# ADVAMED COVID-19 DIAGNOSTIC SUPPLY REGISTRY

AdvaMed members manufacture and ship instruments and high-quality tests that, together with key inputs from our colleagues across the testing ecosystem (e.g., PPE, plastics, swabs, etc.), serve as the backbone of supply for the U.S. testing response to COVID.

AdvaMed has created a national COVID-19 Diagnostic Supply Registry to support state and federal governments in their pandemic responses. AdvaMed and its members are fully committed to providing key data to policymakers and the public in our collective work mobilizing against the pandemic.

AdvaMed is leading this data tracking and analysis effort, driven by thirteen leading diagnostic manufacturers whose tests together comprise ~75-80% of the COVID-19 Molecular IVD tests on the market in the U.S.




## Key Data-Driven Summary of the U.S. COVID Testing Supply

Last updated October 8, 2021

- Across leading COVID diagnostic manufacturers, **~556 million** molecular COVID-19 tests have been shipped since March 2020, including **~448 million commercial tests** and **~108 million extraction reagents**.
- Registry participants collectively shipped **~9.7 million** molecular tests for the week ending October 1st.
- Daily **Molecular tests run** stayed the same compared to the previous week, with an average of **~1.7 million<sup>1</sup>** tests per day last week.
- Additionally: High-quality laboratory-based **Serology/Antibody** and **Antigen** testing are widely available throughout the U.S., with increasing availability of point-of-care testing – including over-the-counter home testing.

## Weekly Molecular (MDx) Tests Shipped & Reported Test Results Nationwide



1. Averaged over the week to account for fluctuations by day of the week. State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests). 2. IVD and LDT molecular diagnostic test shipments. 3. State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests). 4. The differential in tests shipped versus tests run is impacted by the inclusion of antigen data in the molecular tests run number, the share of test shipments that registry participants account for (75-80%) and pooling. When pooling is used, tests run is reported as 1 test per patient in the pool while tests shipped is reported as 1 test per pool.